Compagnie Lombard Odier SCmA Raises Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Compagnie Lombard Odier SCmA has increased its stake in Thermo Fisher Scientific Inc. by 12.2%, holding 280,728 shares, which now represents 1.5% of its portfolio.
• Multiple institutional investors have modified their stakes in Thermo Fisher, with notable increases from Unified Investment Management (16.9%) and Town & Country Bank & Trust (12.1%).
• Thermo Fisher Scientific recently announced a quarterly dividend of $0.43 per share, reflecting a 0.4% annual yield and a dividend payout ratio of 9.95%.

Compagnie Lombard Odier SCmA raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 280,728 shares of the medical research company's stock after purchasing an additional 30,461 shares during the quarter. Thermo Fisher Scientific accounts for about 1.5% of Compagnie Lombard Odier SCmA's portfolio, making the stock its 17th biggest position. Compagnie Lombard Odier SCmA owned approximately 0.07% of Thermo Fisher Scientific worth $113,824,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Unified Investment Management grew its holdings in shares of Thermo Fisher Scientific by 16.9% in the second quarter. Unified Investment Management now owns 968 shares of the medical research company's stock valued at $392,000 after acquiring an additional 140 shares in the last quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO grew its holdings in shares of Thermo Fisher Scientific by 12.1% in the second quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 2,539 shares of the medical research company's stock valued at $1,029,000 after acquiring an additional 274 shares in the last quarter. GSB Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 10.7% in the second quarter. GSB Wealth Management LLC now owns 1,103 shares of the medical research company's stock valued at $447,000 after acquiring an additional 107 shares in the last quarter. Argent Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific by 2.7% in the second quarter. Argent Capital Management LLC now owns 36,284 shares of the medical research company's stock valued at $14,712,000 after acquiring an additional 958 shares in the last quarter. Finally, Hoey Investments Inc. grew its holdings in shares of Thermo Fisher Scientific by 11.3% in the second quarter. Hoey Investments Inc. now owns 1,021 shares of the medical research company's stock valued at $414,000 after acquiring an additional 104 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 over the last ninety days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Down 1.1%

Thermo Fisher Scientific stock opened at $474.54 on Tuesday. The firm has a market cap of $179.19 billion, a price-to-earnings ratio of 27.45, a PEG ratio of 2.56 and a beta of 0.75. The stock has a fifty day simple moving average of $472.99 and a two-hundred day simple moving average of $448.55. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Analyst Upgrades and Downgrades

TMO has been the subject of several research reports. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. UBS Group raised their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Finally, Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research note on Friday, July 11th. Sixteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $588.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.